Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the development of ivonescimab in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). It’s undertaking multiregional Phase III clinical trials. Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab In addition, the company has engaged GORTEC, a European Head and Neck Oncology and ...